Who
Anthony Hunt
Director
Company insider
Files Form 4 as: Director, BioLife Solutions; Director, 908 Devices; Chief Executive Officer, Repligen.
In numbers
- Trades disclosed
- 276
- Buys
- 1
- Sells
- 33
- Bought
- $248K
- Sold
- $94.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 5 May 2014
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code D | —15,046 | filing |
| 11 Jun 2026filed 12 Jun 2026 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —13,656 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —13,656 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,209 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code A | —6,209 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MASS 908 DevicesLife-science tools | SEC FORM 4 Code M | —14,083 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code M | —14,083 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MASS 908 Devicesoption or derivative · Life-science tools | SEC FORM 4 Code M | —14,083 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | MASS 908 DevicesLife-science tools | SEC FORM 4 Code M | —14,083 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $1.2M9,897 at $124.97 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RGEN RepligenBiotechnology | SEC FORM 4 Code F | $1.2M9,897 at $124.97 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —8,170 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —8,170 | filing |
| 4 Dec 2025filed 8 Dec 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Code J | —2,000 | filing |
| 13 Nov 2025filed 14 Nov 2025 | RGEN Repligenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,952 at $0.00 | filing |
| 13 Nov 2025filed 14 Nov 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $269K1,784 at $151.01 | filing |
| 13 Nov 2025filed 14 Nov 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $320K2,100 at $152.17 | filing |
| 13 Nov 2025filed 14 Nov 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $448K2,923 at $153.14 | filing |
| 13 Nov 2025filed 14 Nov 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $386K2,500 at $154.32 | filing |
| 13 Nov 2025filed 14 Nov 2025 | RGEN RepligenBiotechnology | SEC FORM 4 Sold | $466K3,000 at $155.45 | filing |
News
No headline names them, or the companies they trade most, lately.